Twist Bioscience (NASDAQ:TWST) CAO Robert Werner Sells 7,000 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CAO Robert Werner sold 7,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $45.65, for a total value of $319,550.00. Following the completion of the sale, the chief accounting officer owned 58,738 shares in the company, valued at approximately $2,681,389.70. This represents a 10.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Twist Bioscience Stock Performance

Shares of TWST traded down $1.02 during trading hours on Thursday, hitting $47.10. The stock had a trading volume of 2,162,437 shares, compared to its average volume of 1,485,586. The firm has a 50-day moving average price of $36.23 and a 200 day moving average price of $31.84. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $54.74. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of -36.80 and a beta of 2.24. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.33 and a current ratio of 3.78.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The firm had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business’s revenue was up 16.9% compared to the same quarter last year. As a group, research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TWST. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Stephens initiated coverage on shares of Twist Bioscience in a report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price target for the company. Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday. Evercore ISI lifted their target price on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $45.88.

Institutional Trading of Twist Bioscience

Hedge funds have recently bought and sold shares of the business. Quarry LP acquired a new position in shares of Twist Bioscience during the 3rd quarter worth approximately $28,000. Smartleaf Asset Management LLC boosted its stake in Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after buying an additional 442 shares during the last quarter. SBI Securities Co. Ltd. grew its holdings in Twist Bioscience by 68.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after buying an additional 571 shares in the last quarter. National Bank of Canada FI acquired a new stake in shares of Twist Bioscience in the 3rd quarter worth $46,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Twist Bioscience by 15.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after acquiring an additional 302 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.